Search
Formic acid
go.drugbank.com/drugs/DB01942ApprovedInvestigationalIt is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings. … It is commonly used as a preservative and antibacterial agent in livestock feed.
Amrubicin
go.drugbank.com/drugs/DB06263InvestigationalIn 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006.
Medifoxamine
go.drugbank.com/drugs/DB13219ApprovedMedifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity
Prednisolone phosphate
go.drugbank.com/drugs/DB14631ApprovedInvestigationalVet approved[A187463] Prednisolone phosphate was granted FDA Approval on 19 December 1973.[L14144]
Plasma protein fraction (human)
go.drugbank.com/drugs/DB13968ApprovedInvestigational[L2262] The proteins in PPFh are stabilized with sodium caprylate and acetyltryptophan and it contains some electrolytes such as sodium, potassium and chloride.[L2261] … This biologic should come from recovered plasma from whole blood or prepared source plasma. the final product should not include any type of additives.
Bisoxatin
go.drugbank.com/drugs/DB09219ApprovedBisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine [L926]. … It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.
Ancrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnThe defribrinogenation of blood results in an anticoagulant effect. … Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S.
Categories: Complex MixturesChlorzoxazone
go.drugbank.com/drugs/DB00356ApprovedIt is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
Elacridar
go.drugbank.com/drugs/DB04881InvestigationalIn many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. … Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors.
CHGN111
go.drugbank.com/drugs/DB06376ExperimentalNumerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative … CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.